0001645113-20-000134.txt : 20200911 0001645113-20-000134.hdr.sgml : 20200911 20200911161546 ACCESSION NUMBER: 0001645113-20-000134 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200909 FILED AS OF DATE: 20200911 DATE AS OF CHANGE: 20200911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEUNG GABRIEL CENTRAL INDEX KEY: 0001236183 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 201171104 MAIL ADDRESS: STREET 1: C/O PERNIX THERAPEUTICS HOLDINGS, INC. STREET 2: 10 NORTH PARK PLACE, SUITE 201 CITY: MORRISTOWN STATE: NJ ZIP: 07960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 wf-form4_159985533001922.xml FORM 4 X0306 4 2020-09-09 0 0001645113 NovoCure Ltd NVCR 0001236183 LEUNG GABRIEL C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 1 0 0 0 Ordinary Shares 2020-09-09 4 M 0 9114 7.03 A 81159 D Ordinary Shares 2020-09-09 4 S 0 9014 85.388 D 72145 D Ordinary Shares 2020-09-09 4 S 0 100 86.06 D 72045 D Ordinary Shares 2020-09-10 4 M 0 10000 7.48 A 82045 D Ordinary Shares 2020-09-10 4 S 0 10000 90 D 72045 D Options to Buy Ordinary Shares 7.03 2020-09-09 4 M 0 9114 0 D 2023-02-19 Ordinary Shares 9114.0 0 D Options to Buy Ordinary Shares 7.48 2020-09-10 4 M 0 10000 0 D 2024-02-25 Ordinary Shares 10000.0 12173 D On September 9, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 9,014 shares in multiple trades at prices ranging from $85.00 to $85.92. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Fully vested as of the date hereof. By: /s/ Steven Robbins, Attorney in Fact for Kinyip Gabriel Leung 2020-09-11